Skeletal metastasis is common in advanced stages of various cancers, particularly of the prostate and breast carcinoma. 188Re-HEDP (1-hydroxyethane 1, 1-diphosphonic acid) is a clinically established radiopharmaceutical for bone pain palliation of osseous metastasis, and it takes advantage of high bone affinity. The present work aims at elucidating the possible mechanisms of cell killing by 188Re-HEDP in osteosarcoma cells and biodistribution studies in mice.188Re-HEDP complex was prepared by using lyophilized HEDP kits prepared in-house. In vitro cellular uptake in mineralized bone matrix was found to be 13.41% ± 0.46% (at 2 hours), which was reduced to 2.44% ± 0.12% in the presence of excess amounts of unlabeled HEDP ligand. Uptake of 188Re-HEDP in bones of normal Swiss mice in vivo and mineralized bone in vitro indicated its affinity toward the bone matrix. The study also revealed that cellular toxicity and G2/M cell cycle arrest were dose dependent. At higher doses, G2/M cell cycle arrest was observed, which might be the major cause of cell death and a possible mechanism of bone pain relief.
Get full access to this article
View all access options for this article.
References
1.
DasT, BanerjeeS. Radiopharmaceuticals for metastatic bone pain palliation: Available options in the clinical domain and their comparisons. Clin Exp Metastasis, 2017; 34:1.
2.
PaesFM, SerafiniAN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med, 2010; 40:89.
3.
OgawaK, WashiyamaK. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem, 2012; 19:3290.
4.
Di LorenzoG, AutorinoR, CiardielloF, et al.Bone metastases are a severe problem in oncology, since they usually are associated with pain. Oncol Rep, 2003; 10:399.
5.
HarrisonMR, WongTZ, ArmstrongAJ, GeorgeDJ. Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res, 2013; 5:1.
6.
Pandit-TaskarN, BatrakiM, DivgiCR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med, 2004; 45:1358.
7.
ElderRC, YuanJ, HelmerB, et al.Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogues of the radiotherapeutic agent (186)Re-HEDP. Inorg Chem, 1997; 36:3055.
8.
LamMG, de KlerkJM, van RijkPP. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging, 2004; 31:S162.
9.
DasBK, PradhanPK, ShuklaAK, et al.Role of radiosynovectomy in rheumatoid arthritis. J Indian Rheumatol Assoc, 2004; 12:98.
10.
VucinaJ.Technetium-99 m production for use in nuclear medicine. Med Pregl, 2000; 53:631.
11.
ArgyrouM, ValassiA, AndreouM, LyraM. Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging, 2013; 2013:7.
12.
KnappFFJr, ButlerTA. Radionuclide Generators: New Systems for Nuclear Medicine Applications. Washington DC: ACS Symposium Series, American Chemical Society, 1984; 241.
13.
DashA, KnappFFJr (Russ). An overview of radioisotope separation technologies for development of 188 W/188Re radionuclide generators providing 188Re to meet future research and clinical demands. RSC Adv, 2015; 5:39012.
14.
SubramanianG, McAfeeJG, BlairRJ, et al.Technetium-99 m-methylene diphosphonate—A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med, 1975; 16:744.
15.
DomstadPA, CoupalJJ, KimEE, et al.99mTc-hydroxymethane diphosphonate: A new bone imaging agent with a low tin content. Radiology, 1980; 136:209.
16.
CastronovoEP, CallahanRJ. New bone scanning agent: 99mTc-labeled 1-hydroxy-ethylidene-1, 1-disodium phosphonate. J Nucl Med, 1972; 13:823.
17.
CocquytV, KlineWF, GertzBJ, et al.Pharmacokinetics of intravenous alendronate. J Clin Pharmacol, 1999; 39:385.
18.
BushinskyDA, NeumannKJ, AsplinJ, et al.Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int, 1999; 55:234.
19.
LamMG, de KlerkJM, van RijkPP, et al. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem, 2007; 7:381.
20.
RobinsonRJ.Systemic radioisotopic therapy of primary and metastatic bone cancer. J Nucl Med, 1990; 31:1326.
21.
PalmedoH, GuhlkeS, BenderH, et al.Dose escalation study with rhenium-186 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med, 2000; 27:123.
22.
MalliaMB, ShintoAS, KameswaranM, et al.A Freeze-dried kit for the preparation of 188Re-HEDP for bone pain palliation: Preparation and preliminary clinical evaluation. Cancer Biother Radiopharm, 2016; 31:139.
23.
KumarC, KordeA, KumariKV, et al.Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP. Curr Radiopharm, 2013; 6:146.
24.
KumarC, VatsK, LoharSP, et al.Camptothecin enhances cell death induced by 177Lu-EDTMP in osteosarcoma cells. Cancer Biother Radiopharm, 2014; 29:317.
25.
VigneshRC, Sitta DjodyS, JayasudhaE, et al.Effect of ethanol on human osteosarcoma cell proliferatation differentiation and mineralization. Toxicology, 2006; 220:63.
26.
GregoryCA, GunnWG, PeisterA, et al.An Alizarin red based assay of mineralization by adherent cells in culture: Comparison with cetylpyridinium chloride extraction. Anal Biochem, 2004; 329:77.
27.
LuzMA, AprikianAG. Preventing bone complications in advanced prostate cancer. Curr Oncol, 2010; 17:S65.
28.
ChenYC, SosnoskiDM, MastroAM. Breast cancer metastasis to the bone: Mechanisms of bone loss. Breast Cancer Res, 2010; 12:215.
29.
MitterhauserM, ToegelS.What to consider in the development of new bone seekers: Mechanistic and tracer-related aspects. Nucl Med Biol, 2008; 35: 817.
30.
SchwartzZ, ShaniJ, SoskolneWA, et al.Uptake and biodistribution of Technetium-99 m-MD32P during rat tibial bone repair. J Nucl Med, 1993; 34:104.
31.
SelaJ, ShaniJ, KohaviD, et al.Uptake and biodistribution of 99mtechnetium methylene-[32P] diphosphonate during endosteal healing around titanium, stainless steel and hydroxyapatite implants in rat tibial bone. Biomaterials, 1995; 18:1373.
32.
MitterhauserM, TögelS, WadsakW, et al.Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [111In], [99mTc], [153Sm] and [188Re] on bone compartments: A new model for the pre vivo-evaluation of bone seekers?. Bone, 2004; 34:835.
33.
KinishiD.99mTc-MDP accumulation mechanism in bone. Oral Surg Oral Med Oral Pathol, 1993; 75:23.
34.
NicoliniF, BurmistrovaO, MarreroMT, et al.Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells. Mol Carcinog, 2014; 53:939.
35.
ZhangW, GaoR, YuY, et al.Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2/M phase arrest in a p53-independent pathway. Mol Med Rep, 2015; 11:3148.
36.
SakA, WurmR, EloB, et al.Increased radiation‐induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligo deoxynucleotides targeting p53 and p21 WAF1/CIP1. Cancer Gene Ther, 2003; 10:926.
37.
FernetM, Mégnin‐ChanetF, HallJ, et al.Control of the G2/M checkpoints after exposure to low doses of ionizing radiation: Implications for hyper‐radiosensitivity. DNA Repair (Amst), 2010; 9:48.
38.
WangC, WangJ, JiangH, et al.In vitro study on apoptosis induced by strontium‐89 in human breast carcinoma cell line. J Biomed Biotechnol, 2011; 2011:541487.
39.
ErikssonD, BlombergJ, LindgrenT, et al.Iodine‐131 induces mitotic catastrophes and activates apoptotic pathways in HeLa Hep2 cells. Cancer Biother Radiopharm, 2008; 23:541.
